Mirum Pharmaceuticals (MIRM) concentration risks

The company's disclosed concentration is a single channel dependency: both Ctexli and Cholbam are commercialized in the United States through one specialty pharmacy. By disclosed size this is a high-share exposure, and the character is dependency — a sole commercial channel for two approved products means that any disruption to the specialty pharmacy relationship would directly affect the company's ability to distribute its entire U.S. product portfolio without an immediately available backup. There are no disclosed customer, geographic, supplier, product, or regulatory concentrations on record beyond this channel dependency. The risk is therefore operationally focused: the specialty pharmacy controls order fulfillment, patient access, and the logistics of product distribution. A contract dispute, operational failure, compliance issue, or business disruption at the single specialty pharmacy would have a high-share impact on the company's commercial operations given that it is the sole point of patient access in the United States for both products. On balance, the concentration profile is narrow but operationally consequential. The channel dependency is the dominant variable: specialty pharmacy continuity, contract terms, and operational reliability are the key factors investors should monitor. The absence of any other disclosed concentration means this single relationship represents the most immediate actionable risk in the disclosed profile. Development of backup distribution arrangements would be the principal mitigation that investors would look for to reduce this exposure over time.

For the engine’s reasoning on MIRM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.